
    
      Solid organ transplant recipients are treated with immunosuppressive drugs to prevent
      rejection of their grafts. The most frequently important maintenance immunosuppressive drugs
      in Europe are calcineurin inhibitors.

      For a number of these compounds drug patents have expired in recent years and generic
      formulations have entered the market. There is considerable debate regarding the efficacy and
      safety of generic drug substitution in solid organ recipients.
    
  